argenx ADR had its Relative Strength (RS) Rating upgraded from 88 to 91 Friday.
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history reveals that the best-performing stocks tend to have an RS Rating north of 80 as they begin their biggest runs.
Here Are 3 Keys For Successful Stock Investing
argenx ADR is building a consolidation with a 678.21 buy point. See if the stock can clear the breakout price in heavy volume.
argenx ADR posted 0% earnings growth in the latest quarterly report, while sales growth came in at 82%.
argenx ADR earns the No. 10 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
